Looking at the patent information registration platform for listed drugs in China, we find that...

In order to protect the legitimate rights and interests of drug patent holders, encourage new drug research and promote the development of high-level generic drugs, the State Council’s drug regulatory authority formulated the "Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes (Trial)" (hereinafter referred to as the "Measures") and organized the establishment China's listed drug patent information registration platform, for drug marketing license holders to register drug-related patent information registered in China

Article 11 of the "Measures" stipulates that the first chemical generic drug that successfully challenged the patent and was approved to be listed on the market shall be granted a period of market exclusivity

Starting from July 4th, the Chinese listed drug patent information registration platform has been officially launched.

Judging from the currently registered information, the types of patents not only include compounds, pharmaceutical compositions and medical uses, but also include formulations, preparation methods, crystal forms, salts, etc.

In the patent information registration platform for listed drugs in China, it is found that some companies have applied for patent term compensation, including vedictuomab for injections, imitenofovir tablets, hytropopaethanolamine tablets and injections Tacitep

At the same time, the patent information registration platform for listed drugs in China also provides patent invalidity and litigation related information, further reminding generic drug companies of the validity of the patent

In addition, from the amount of drugs registered in the patent information registration platform for listed drugs in China, it can be seen that foreign companies such as Merck, Novartis, AZ, and Roche have mostly declared drugs in China, and they are strong opponents of domestic innovative drug companies